Navigation Links
KV Pharmaceutical Company Announces NYSE Listing Extension
Date:12/28/2007

NYSE Agrees to a Trading Extension of KV's Securities until February 15,

2008

ST. LOUIS, Dec. 28 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb) a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology differentiated branded and generic/non-branded prescription pharmaceutical products, announced today that NYSE Regulation, Inc. has granted KV's request for a trading extension through February 15, 2008 for its securities, subject to ongoing reassessment. The extension was required under the NYSE's rules because the Company has been delayed in filing its fiscal 2007 Annual Report on Form 10-K. The Company expects to have all outstanding quarterly and annual SEC reports for fiscal 2007 filed with the SEC by February 15, 2008

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology-distinguished products through ETHEX Corporation, a national leader in pharmaceuticals that compete with branded products, and Ther-Rx Corporation, its branded prescription pharmaceutical subsidiary.

For further information about KV Pharmaceutical Company, please visit the Company's corporate website at http://www.kvpharmaceutical.com.

Safe Harbor

The information in this release may contain various forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 ("PSLRA") and which may be based on or include assumptions concerning KV's operations, future results and prospects. Such statements may be identified by the use of words like "plans", "expect", "aim", "believe", "projects", "anticipate
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Mayo Clinic researchers have used next generation genomic analysis ... cancer tumors have similar genetic origins, which may help ... in the journal Cancer Research . , "This ... next generation sequencing in adjacent Gleason patterns in the ... in pathology," says ,John Cheville, M.D., Mayo Clinic pathologist ...
(Date:5/23/2013)... May 23, 2013 Dr. Katherine Ahn ... charitable organization in Orange County, OCCares , will hold ... County. The event details are as follows: , Sunday ... Auditorium, 13732 Clinton Street, Garden Grove, CA 92843 , The ... music by Christian vocalists Charmaine & Jonathan Thulin. There ...
(Date:5/23/2013)... Click here to read the full ... increasingly seeing their success develop through merger and ... according to new research carried out by MaRS , ... has compiled its research into a series of articles ... research have shown the general trend that the success ...
(Date:5/23/2013)... Cheap Concert Tickets announces that Paul McCartney will ... North America. This well known ticket website has slashed ... help McCartney fans see Sir Paul live in concert. ... is also offering the customer appreciation code SAVE for additional ... she is also a huge McCartney fan and plans to ...
(Date:5/23/2013)... (HealthDay News) -- Symptoms of borderline personality disorder ... diagnosis and treatment. But researchers in Canada say ... unique to borderline personality disorder: a tendency to ... "They have difficulty processing facial emotions and will ... said Anthony Ruocco, a clinical neuropsychologist and assistant ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic genomic analysis lends insight to prostate cancer 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 2Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 3Health News:Merrill DataSite Releases New Comments: Trends amidst Canadian and US Tech M&A 4Health News:Paul McCartney Tickets: Prices Slashed on Paul McCartney Tickets in Austin, Brooklyn, Tulsa, Memphis Washington DC, Milwaukee, Boston, Indianapolis, Regina and Seattle 2Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 2Health News:People With Borderline Personality Disorder May Misinterpret Facial Emotions 3
... New Non-Steroidal Skin Treatment to Treat All ... with Steroids, BARRINGTON, Ill., Oct. 19 Steroids have ... abuse. There must be reasons why,people use steroid products on ... largest organ of the human body, and it needs to ...
... 19 Uroplasty, Inc. (Amex:,UPI) announced today that ... Securities and Exchange Commission in anticipation of a ... of its,common stock. Craig-Hallum Capital Group and ... connection with this proposed public offering.,A copy of ...
... Scans, Oct 26 & 27, as Part of Clinical Study., CHICAGO, ... Stage III or Stage IV ... at no charge as part of a clinical trial. ... cancer that tests positive for a protein called human ...
... Holdings, Inc. and its,operating subsidiary, US Oncology, Inc., ... November 8, 2007. A conference call and ... EST, for the company,s bondholders following the distribution ... US Oncology,s management,team will discuss the financial results. ...
... Oct. 18 West Pharmaceutical,Services, Inc. (NYSE: ... announcement that it has decided to discontinue marketing ... to the,Company,s customer, Nektar Therapeutics, Inc. The Company,s ... the Exubera inhalation device for Nektar. "We ...
... cancer patients with the poorest prognosis -- those with a ... may survive longer with a drug that chokes off ... by researchers at Dukes Preston Robert Tisch Brain Tumor Center, ... and a standard chemotherapy agent, may increase the amount of ...
Cached Medicine News:Health News:Steroids Are Abused for Skin, Not Just Muscles 2Health News:Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock 2Health News:Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock 3Health News:Brain Screenings Offered to Breast Cancer Patients During Breast Cancer Awareness Month 2Health News:West Pharmaceutical Services Issues Statement on Exubera 2Health News:West Pharmaceutical Services Issues Statement on Exubera 3Health News:West Pharmaceutical Services Issues Statement on Exubera 4Health News:Drug combination might offer hope for patients deadly brain tumors 2
(Date:5/23/2013)... 2013  Haemonetics Corporation (NYSE: HAE ) announced ... EVP-Business Development, will present at The Deutsche Bank 38 th ... MA on May 29, 2013 at 1:30pm Eastern ... The public may access Mr. Lindop,s presentation live via ... Haemonetics (NYSE: HAE ) is a ...
(Date:5/23/2013)...  TeamHealth Medical Call Center (THMCC), a premier ... lines, announces its newly formed Clinical Advisory Committee. ... leaders, provides clinical expertise to advance THMCC,s purpose ... hospital clients, physician clients and patients. ... imperative to continuously advance our services and improve ...
(Date:5/23/2013)... ARBOR, Mich. , May 23, 2013  Every day, ... flow of air to his lungs. April and ... the dire predictions weren,t true. "Quite a few ... the hospital alive," says April Gionfriddo , ... were desperate. Anything that would work, we would take it ...
Breaking Medicine Technology:TeamHealth Medical Call Center Forms Clinical Advisory Committee 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4
... Novavax, Inc. (Nasdaq: NVAX) a clinical-stage ... results from its 2009 H1N1 virus-like particle (VLP) pandemic ... 7th World Health Organization Meeting (WHO) on Evaluation of ... held at the WHO headquarters in Geneva, Switzerland where ...
... Technologies Corporation (Nasdaq: LIFE ), today ... winners of the European Ion Torrent Personal Genome Machine ... http://photos.prnewswire.com/prnh/20110216/MM49339LOGO ) Each scientist will receive an Ion ... Torrent sequencing technology, these scientists will be able to give ...
Cached Medicine Technology:NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting 2NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting 3NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting 4NOVAVAX Presents Final Results from H1N1 Influenza Vaccine Trial at World Health Organization Meeting 5Life Technologies Announces Visionary Winners of the Ion Torrent PGM Grants Program in Europe 2Life Technologies Announces Visionary Winners of the Ion Torrent PGM Grants Program in Europe 3Life Technologies Announces Visionary Winners of the Ion Torrent PGM Grants Program in Europe 4Life Technologies Announces Visionary Winners of the Ion Torrent PGM Grants Program in Europe 5
PG Magnum Ring Curettes, total length 12.6" (32 cm), handle length 7.8" (20 cm), handle diameter 1.12" (3 cm), working distance 4.7" (12 cm), dual-coned, precision sharpened rings....
Karlin XL Magnum Cup Curettes, extra long (XL) curettes, black handles, lightweight, length 13 1/4" (33.7 cm), handle length 8 1/2" (21 cm), handle diameter 1 1/4" (32 cm)....
XL Cervical Curette comes with a bayonet design and satin black handles having instrument length 9.5" (24 cm), working distance4.1" (10.4 cm) and handle width 0.6" (1.5 cm)....
Caspar Curette, 250 mm, 10"....
Medicine Products: